Review
Biochemistry & Molecular Biology
Chang Youn Lee, In Soo Ryu, Jin-Hyeob Ryu, Hyun-Jeong Cho
Summary: Alzheimer's disease is a progressive neurodegenerative disorder, with miRNAs playing a crucial role in its pathological processes. Limitations of current pharmaceutical therapies have led to research on miRNA-based next-generation therapies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Biochemistry & Molecular Biology
Long Wang, Xindong Shui, Yuelin Diao, Duoting Chen, Ying Zhou, Tae Ho Lee
Summary: This review summarizes the role of microRNAs in Alzheimer's disease. MicroRNAs can directly regulate the expression of Alzheimer's disease-related proteins, regulate the alternative splicing of tau and amyloid precursor protein, and modulate inflammatory responses. Additionally, circulating microRNAs in the blood may serve as noninvasive biomarkers for diagnosing Alzheimer's disease. Furthermore, microRNA-based therapeutics are being investigated as potential options for Alzheimer's disease treatment.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Biochemistry & Molecular Biology
Filippa Lo Cascio, Paola Marzullo, Rakez Kayed, Antonio Palumbo Piccionello
Summary: This review highlights recent research on modifying the structure of curcumin to search for new effective therapeutic agents against neurodegenerative diseases, with a particular focus on Alzheimer's disease.
Article
Multidisciplinary Sciences
Romany Abskharon, Michael R. Sawaya, David R. Boyer, Qin Cao, Binh A. Nguyen, Duilio Cascio, David S. Eisenberg
Summary: In this study, the structure of RNA-bound tau protein fibrils was determined using cryo-EM. The findings demonstrate that RNA is necessary for the integrity of the fibrils and reveal a potential mechanism for the nucleating effects of RNA in neurodegenerative diseases. This research provides insight into the formation of protein aggregates in these diseases.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2022)
Article
Neurosciences
Joseph R. Winer, Allison Morehouse, Laura Fenton, Theresa M. Harrison, Lylian Ayangma, Mark Reed, Samika Kumar, Suzanne L. Baker, William J. Jagust, Matthew P. Walker
Summary: This study found that early-stage tau and Aβ deposition in Alzheimer's disease can impact sleep, with tau burden leading to worse objective sleep and Aβ burden associated with decreased self-reported sleep quality. Aβ deposition also predicts a mismatch between objective and subjective sleep evaluation, with individuals underestimating their sleep, which is further linked to worse executive function.
JOURNAL OF NEUROSCIENCE
(2021)
Article
Clinical Neurology
Amelia Strom, Leonardo Iaccarino, Lauren Edwards, Orit H. Lesman-Segev, David N. Soleimani-Meigooni, Julie Pham, Suzanne L. Baker, Susan M. Landau, William J. Jagust, Bruce L. Miller, Howard J. Rosen, Maria Luisa Gorno-Tempini, Gil D. Rabinovici, Renaud La Joie
Summary: Posterior cortical hypometabolism measured with F-18-fluorodeoxyglucose (FDG)-PET is a marker of neurodegeneration in Alzheimer's disease, and it is mainly associated with structural neurodegeneration and tau pathology, rather than amyloid pathology.
Review
Biochemistry & Molecular Biology
Yuanxin Zhao, Buhan Liu, Jian Wang, Long Xu, Sihang Yu, Jiaying Fu, Xiaoyu Yan, Jing Su
Summary: Neuroinflammation mediated by microglia is a common feature in neurodegenerative diseases. The accumulation of Aβ and tau proteins can disrupt the metabolism of microglia, leading to neuroinflammation.
Article
Clinical Neurology
Ashvini Keshavan, Josef Pannee, Thomas K. Karikari, Juan Lantero Rodriguez, Nicholas J. Ashton, Jennifer M. Nicholas, David M. Cash, William Coath, Christopher A. Lane, Thomas D. Parker, Kirsty Lu, Sarah M. Buchanan, Sarah E. Keuss, Sarah-Naomi James, Heidi Murray-Smith, Andrew Wong, Anna Barnes, John C. Dickson, Amanda Heslegrave, Erik Portelius, Marcus Richards, Nick C. Fox, Henrik Zetterberg, Kaj Blennow, Jonathan M. Schott
Summary: The study compared three different blood-based techniques for identifying early stage Alzheimer's disease, with mass spectrometry plasma measures performing significantly better than other measures.
Article
Clinical Neurology
Ashvini Keshavan, Josef Pannee, Thomas K. Karikari, Juan Lantero Rodriguez, Nicholas J. Ashton, Jennifer M. Nicholas, David M. Cash, William Coath, Christopher A. Lane, Thomas D. Parker, Kirsty Lu, Sarah M. Buchanan, Sarah E. Keuss, Sarah-Naomi James, Heidi Murray-Smith, Andrew Wong, Anna Barnes, John C. Dickson, Amanda Heslegrave, Erik Portelius, Marcus Richards, Nick C. Fox, Henrik Zetterberg, Kaj Blennow, Jonathan M. Schott
Summary: The study compared three different blood-based techniques to detect amyloid PET positivity in dementia-free individuals, finding that mass spectrometry plasma measures performed significantly better than other measures, with higher sensitivity and specificity for detecting amyloid PET positivity.
Article
Medicine, General & Internal
Giulia Bivona, Matilda Iemmolo, Tommaso Piccoli, Luisa Agnello, Bruna Lo Sasso, Marcello Ciaccio, Giulio Ghersi
Summary: Alzheimer's disease (AD) is the most common form of cognitive decline, characterized by aggregates of A beta and tau protein. In addition to A beta deposition, inflammation and microglia activation in the brain may also play a role in the pathogenesis of AD.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Biochemistry & Molecular Biology
Huiqin Zhang, Wei Wei, Ming Zhao, Lina Ma, Xuefan Jiang, Hui Pei, Yu Cao, Hao Li
Summary: Extracellular neuritic plaques and intracellular neurofibrillary tangles, composed of amyloid-beta and phosphorylated tau protein respectively, are hallmark proteins of Alzheimer's disease. The interactions between these proteins have been extensively studied, with A beta accelerating tau phosphorylation, tau mediating A beta toxicity, and potential synergistic effects on microglial cells and astrocytes. Understanding these interactions may lead to new interventions against Alzheimer's disease.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2021)
Article
Neurosciences
Philip S. Insel, Michael C. Donohue, David Berron, Oskar Hansson, Niklas Mattsson-Carlgren
Summary: The study revealed that changes in key pathological markers A beta and tau in Alzheimer's disease may occur several decades or years before A beta-positivity, while cognitive dysfunction may appear 4-6 years before A beta-positivity, providing potential windows for specific treatments.
Article
Public, Environmental & Occupational Health
Chris Ho Ching Yeung, Kathleen Wen Din Lau, Shiu Lun Au Yeung, C. Mary Schooling
Summary: Genetic associations with plasma amyloid species, CSF total tau, and phosphorylated tau(181) were not found to be associated with Alzheimer's disease, while the effects of CSF Aβ(42) showed inconsistencies between different studies.
EUROPEAN JOURNAL OF EPIDEMIOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Lei Zhang, Zhuo Wang, Xueling Yuan, Rubo Sui, Mojtaba Falahati
Summary: Heptelidic acid inhibits tau fibrillization in a concentration-dependent manner and reduces neurotoxicity associated with tau amyloid, making it a potential candidate for preventive care studies.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
(2021)
Review
Pharmacology & Pharmacy
Mohammad Rafi Khezri, Keyvan Yousefi, Negin Mahboubi, Darya Hodaei, Morteza Ghasemnejad-Berenji
Summary: Alzheimer's disease (AD) is a common neurodegenerative disorder worldwide, and its association with diseases like diabetes has been well-studied. Metformin, a medication commonly used for type 2 diabetes, has shown potential disease-modifying effects on various aspects of AD pathophysiology.
BIOCHEMICAL PHARMACOLOGY
(2022)
Article
Neurosciences
Annerieke S. R. Sierksma, Laurence de Nijs, Govert Hoogland, Tim Vanmierlo, Fred W. van Leeuwen, Bart P. F. Rutten, Harry W. M. Steinbusch, Jos Prickaerts, Daniel L. A. van den Hove
JOURNAL OF ALZHEIMERS DISEASE
(2016)
Article
Clinical Neurology
Juan Antonio Garcia-Leon, Alfredo Cabrera-Socorro, Kristel Eggermont, Ann Swijsen, Joke Terryn, Raheem Fazal, FatemehArefeh Nami, Laura Ordovas, Ana Quiles, Frederic Lluis, Lutgarde Serneels, Keimpe Wierda, Annerieke Sierksma, Mohamed Kreir, Francisco Pestana, Philip Van Damme, Bart De Strooper, Lieven Thorrez, Andreas Ebneth, Catherine M. Verfaillie
ALZHEIMERS & DEMENTIA
(2018)
Article
Neurosciences
Tim Vanmierlo, Jochen De Vry, Ellis Nelissen, Annerieke Sierksma, Nadia Roumans, Harry W. M. Steinbusch, Lawrence P. Wennogle, Daniel van den Hove, Jos Prickaerts
MOLECULAR AND CELLULAR NEUROSCIENCE
(2018)
Article
Anatomy & Morphology
Marijke A. M. Lemmens, Annerieke S. R. Sierksma, Bart P. F. Rutten, Frank Dennissen, Harry W. M. Steinbusch, Paul J. Lucassen, Christoph Schmitz
BRAIN STRUCTURE & FUNCTION
(2011)
Article
Medicine, Research & Experimental
Pierre Lau, Koen Bossers, Rekin's Janky, Evgenia Salta, Carlo Sala Frigerio, Shahar Barbash, Roy Rothman, Annerieke S. R. Sierksma, Amantha Thathiah, David Greenberg, Aikaterini S. Papadopoulou, Tilmann Achsel, Torik Ayoubi, Hermona Soreq, Joost Verhaagen, Dick F. Swaab, Stein Aerts, Bart De Strooper
EMBO MOLECULAR MEDICINE
(2013)
Article
Pharmacology & Pharmacy
Annerieke S. R. Sierksma, Daniel L. A. van den Hove, Harry W. M. Steinbusch, Jos Prickaerts
EUROPEAN JOURNAL OF PHARMACOLOGY
(2010)
Article
Geriatrics & Gerontology
Annerieke S. R. Sierksma, Jos Prickaerts, Leonidas Chouliaras, Somayeh Rostamian, Lore Delbroek, Bart P. F. Rutten, Harry W. M. Steinbusch, Daniel L. A. van den Hove
NEUROBIOLOGY OF AGING
(2013)
Article
Biochemistry & Molecular Biology
Annerieke S. R. Sierksma, Tim Vanmierlo, Jochen De Vry, Marjolein E. A. Raijmakers, Harry W. M. Steinbusch, Daniel L. A. van den Hove, Jos Prickaerts
NEUROCHEMISTRY INTERNATIONAL
(2012)
Article
Neurosciences
A. S. R. Sierksma, D. L. A. van den Hove, F. Pfau, M. Philippens, O. Bruno, E. Fedele, R. Ricciarelli, H. W. M. Steinbusch, T. Vanmierlo, J. Prickaerts
Article
Multidisciplinary Sciences
Eva L. van Donkelaar, Koen R. D. Vaessen, Jodi L. Pawluski, Annerieke S. Sierksma, Arjan Blokland, Ramon Canete, Harry W. M. Steinbusch
Article
Neurosciences
Annerieke Sierksma, Ashley Lu, Evgenia Salta, Elke Vanden Eynden, Zsuzsanna Callaerts-Vegh, Rudi D'Hooge, David Blum, Luc Buee, Mark Fiers, Bart De Strooper
MOLECULAR NEURODEGENERATION
(2018)
Review
Multidisciplinary Sciences
Annerieke Sierksma, Valentina Escott-Price, Bart De Strooper
Article
Multidisciplinary Sciences
Ganna Leonenko, Emily Baker, Joshua Stevenson-Hoare, Annerieke Sierksma, Mark Fiers, Julie Williams, Bart de Strooper, Valentina Escott-Price
Summary: Polygenic Risk Scores for Alzheimer's disease offer unique possibilities for reliably identifying individuals at high and low risk. The study shows that the best prediction accuracy is achieved with a model including APOE and a polygenic score excluding APOE. Standardizing PRS against the population mean makes individuals' scores comparable between studies.
NATURE COMMUNICATIONS
(2021)
Review
Neurosciences
Rafaela Policarpo, Annerieke Sierksma, Bart De Strooper, Constantin d'Ydewalle
Summary: Recent advances in RNA sequencing technologies have revealed the significance of long non-coding RNAs (lncRNAs) in modulating protein-coding gene expression, especially in the central nervous system. Therefore, lncRNAs are gaining attention as potential novel therapeutic targets for brain disorders.
FRONTIERS IN MOLECULAR NEUROSCIENCE
(2021)